Cord blood stem cell transplant is becoming increasingly important for treatment of life-threatening diseases and debilitating conditions. Umbilical cord blood stem cells are less prone to rejection than bone marrow or peripheral blood stem cells.
A team of South Korean researchers, headed by Prof. Kang Kyung-sun of Seoul National University, has successfully grown pancreatic beta cells from umbilical cord blood stem cells of newborn babies. The stem cells are able to secrete insulin, the hormone necessary for treatment of diabetes. The ability of cord blood stem cells to differentiate, or change into other types of cells in the body is a new discovery that holds great promise for improving the treatment of some of the most common diseases including diabetes. This achievement would be highlighted by The Biochemical and Biophysical Research Communications, the U.S.-based weekly, that documents breakthrough papers in biotechnology.
Similar breakthroughs have been achieved by scientists throughout the world. Researchers at the University of Newcastle, in Dublin, produced a ‘mini liver' from cord blood stem cells. The technique will be developed to create a full-sized, fully functioning liver. Tissues from mini-livers will be used to test new drugs. Researchers are hopeful that within five years, pieces of the tissue can be used to repair damaged livers and within 15 years, actual liver transplants may be done using lab-grown livers made from cord blood. This is a significant achievement that can potentially develop treatments for liver diseases.
